-
Neuropsychiatric Disease and Treatment
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies
Review
(3138) Views (459) Full article downloads
Authors: Prashant Gajwani, David J Muzina, David E Kemp, Keming Gao, Joseph R Calabrese
Published Date January 2007
Volume 2007:3(6) Pages 847 - 853
DOI: http://dx.doi.org/10.2147/NDT.S1636
Prashant Gajwani1, David J Muzina2, David E Kemp3, Keming Gao1, Joseph R Calabrese1
1Case Western Reserve University (CWRU) School of Medicine, 2Cleveland Clinic Lerner College of Medicine of CWRU, 3Case Western Reserve University, Cleveland OH, USA
Abstract: The essential features of bipolar affective disorder involve the cyclical occurrence of high (manic or hypomanic episodes) and low mood states. Depressive episodes in both bipolar I and II disorder are more numerous and last for longer duration than either manic or hypomanic episodes. In addition depressive episodes are associated with higher morbidity and mortality. While multiple agents, including all 5 atypical antipsychotics, have demonstrated efficacy and earned US FDA indication for manic phase of bipolar illness, the acute treatment of bipolar depression is less well-studied. The first treatment approved by the US FDA for acute bipolar depression was the combination of the atypical antipsychotic olanzapine and the antidepressant fluoxetine. Recently, quetiapine monotherapy has demonstrated efficacy in the treatment of depressive episodes associated with both bipolar I and II disorder and has earned US FDA indication for the same.
Keywords: bipolar disorder, quetiapine, BOLDER studies
Readers of this article also read:
Quetiapine in the treatment of schizophrenia
Quetiapine monotherapy for bipolar depression
New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
"If we only got a chance.” Barriers to and possibilities for a more health-promoting health service
Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism
Levels of circulating homocysteine, vitamin B6, vitamin B12, and folate in different types of open-angle glaucoma
Traditional and new strategies in the primary prevention of eating disorders: a comparative study in Spanish adolescents
Obesity and respiratory diseases
Reorientation to more health promotion in health services – a study of barriers and possibilities from the perspective of health professionals
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Journal Indexing
See where all the Dove Press journals are indexed
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor
- Implementing the 2009 Institute of Medicine recommendations on resident physician work hours, supervision, and safety
- Moderate alcohol consumption and cognitive risk
- Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference




